This paper is in the following e-collection/theme issue:

Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1520) JMIR Theme Issue: COVID-19 Special Issue (2461)

Published on in Vol 6, No 3 (2020): Jul-Sep

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/19538, first published .
Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir

Authors of this article:

Guosheng Yin1 Author Orcid Image ;   Chenyang Zhang1 Author Orcid Image ;   Huaqing Jin1 Author Orcid Image
Article Authors Cited by (5) Tweetations (1) Metrics

Journals

  1. Lin H, Liu S, Levin M, Williamson J, Bouvier N, Aberg J, Reich D, Egorova N. Informative Censoring—A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data. Life 2023;13(1):210 View
  2. Peng L, Gao L, Wu X, Fan Y, Liu M, Chen J, Song J, Kong J, Dong Y, Li B, Liu A, Bao F. Lung Organoids as Model to Study SARS-CoV-2 Infection. Cells 2022;11(17):2758 View
  3. Govindarajulu U. COVID-19 Research and p -Values. CHANCE 2023;36(3):35 View
  4. Ramamoorthy J, Ganapathy D, Pandurangan K, Ahmed N, Maiti S. Awareness on current status of usage of ritonavir in the management of covid among dental students. Journal of Advanced Pharmaceutical Technology & Research 2022;13(Suppl 1):S228 View
  5. McCarthy M. The first five years of SARS-CoV-2: inpatient treatment updates and future directions. Expert Opinion on Pharmacotherapy 2024;25(14):1873 View